Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - captopril - oral tablet - 50mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - captopril - oral tablet - 50mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - captopril - oral tablet - 50mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - captopril - oral tablet - 50mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

crescent pharma ltd - captopril - oral tablet - 50mg

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - captopril 25 mg - captopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension. the blood pressure lowering effects of captopril and thiazides are approximately additive. this fixed combination drug may be used as initial therapy or substituted for previously titrated doses of the individual components. when captopril and hydrochlorothiazide are given together it may not be necessary to administer captopril in divided doses to attain blood pressure control at trough (before the next dose). also, with such a combination, a daily dose of 15 mg of hydrochlorothiazide may be adequate. treatment may, therefore, be initiated with captopril and hydrochlorothiazide tablets 25 mg/15 mg once daily. subsequent titration should be with additional doses of the components (captopril, hydrochlorothiazide) as single agents or as captopril and hydrochlorothiazide tablets 50 mg/15 mg, 25 mg/25 mg, or 50 mg/25 mg (see dosage and administration). in using captopril and hydrochlorothiazide, consideration should be give

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 12.5 mg - hypertension: captopril tablets us?are indicated for the teatment of hypertension. tn using captopril, conslderallon should be gtven to the risk of neutropenia!agranutocytosls (seewarnings). captoprll maybe used as initial therapy for patientswilh normal renal function, in whomthe rlskls relatively low. in patients with impaired renal function, particularly those wfth collagen vascular olseas6, captopril should be resened for,hypertenslves who have either developed unacceptable side effecls on otherdrugs, orhave failed to responq satislactorily 10drug combinations. captopril is effective alone and in combination with other antihypertensive agents, ~peclally thiazide-type diuretics. the blood pressure lowering effecls of captoprif and thlazldes are approximalaly a

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

apotex nz ltd - captopril 50mg;  ;   - tablet - 50 mg - active: captopril 50mg     excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose - hypertension captopril is indicated for the treatment of hypertension in adult and paediatric patients. it may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are additive.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

legacy pharmaceutical packaging - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 12.5 mg - hypertension : captopril tablets usp are indicated for the treatment of hypertension. in using captopril, consideration should be given to the risk of neutropenia/ agranulocytosis (see warnings ). captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. heart failure : captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require the presen

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 25 mg - hypertension: captopril tablets, usp are indicated for the treatment of hypertension. in using captopril, consideration should be given to the risk of neutropenia/ agranulocytosis (see warnings). captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. heart failure: captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require the presence